TKThomas Klopstock

Thomas Klopstock

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thomas Klopstock has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Visual acuity changes in idebenone treatment‑naïve patients with Leber hereditary optic neuropathy: insights from the CRS-2 study

    by Maciej R. Krawczynski, Judith van Everdingen, Bart P. Leroy, Christophe Verny, Nöel J. C. Bauer, Cécile Andris, Birgit Lorenz, Marcela Votruba, Claudia Priglinger, Neringa Jurkute, et al.

    Objective: Case Record Survey (CRS)-2 was an international, multicenter, retrospective study designed to characterize the natural history of vision loss and spontaneous recovery in patients with Leber hereditary optic neuropathy (LHON). Methods: Case records of idebenone treatment-naïve patients aged ≥12 years, with mitochondrial DNA (mtDNA) variants m.3460G>A, m.11778G>A or m.14484 T>C, onset of symptoms (OoS) after 1999, and ≥2 visual acuity (VA) assessments within 5 years of OoS were analyzed. Disease phases were subacute/dynamic (≤1 year) or chronic (>1 year from OoS). Separate analyses were performed for eyes with VA assessments within 12 or 24±3 months from baseline (first VA assessment after OoS in each eye). Outcomes included: spontaneous clinically relevant recovery (sCRR; improvement from off-chart to ≤1.6 logMAR, or ≥0.2 logMAR if on-chart), sCR stabilization (sCRS; maintenance of VA A variant (71.7%). The primary endpoint was observed in 20.8% (n=20/96) of eyes. Spontaneous visual outcomes varied by disease phase, mtDNA variant, sex, and age at OoS. Conclusions: CRS-2 provides insights into LHON natural history and suggests the disease course may be more dynamic than previously reported, with spontaneous VA changes occurring well into the chronic phase. Trial registration: ClinicalTrials.gov NCT02796274, May 2016.

  • KCNA2 ‐Associated Hereditary Spastic Paraplegia: Clinical Characteristics and Rationale for Targeted Treatment

    by Christian M. Boßelmann, Martin Vyhnalek, Zuzana Blichova, Ludmila Novotna, Anna Uhrova Meszarosova, Petra Havránková, Elena Kuster, Robert J. Lauerer, Ulrike B.S. Hedrich, Hang Lyu, et al.

    Background: A single recurrent variant, NM_004974.4( KCNA2 ):c.881G>A:p.(Arg294His), causes hereditary spastic paraplegia (HSP) through a unique variant‐specific mechanism. Data from paralogous variants suggest that this may be a druggable mechanism. Objective: The objective of this work is to give an overview of the clinical spectrum and course of KCNA2 ‐p.(Arg294His)‐associated HSP (HSP‐ KCNA2 ) and report treatment with eplerenone, a potassium‐sparing diuretic. Methods: In this retrospective study, we recruited individuals with the variant of interest through international rare disease networks. Treatment with eplerenone was done as off‐label use, and outcome measures were recorded during routine clinical care. Results: We report the clinical characteristics of 23 individuals from 17 families with HSP‐ KCNA2 . We observed a consistent core phenotype of abnormal evoked potentials (100%), cerebellar ataxia (83%), and lower limb spasticity (70%). Childhood‐onset was more commonly associated with epilepsy (odds ratio, 4.16; P = 0.042), and 52% had developmental delay. Progression of motor disability was slow even in childhood onset. We observed full (100%) penetrance and estimated the prevalence to be 0.18 to 0.69 case per million. Treatment with eplerenone was associated with a decrease on the Scale for the Assessment and Rating of Ataxia (Cohen's d = −1.8; −7.9% change from baseline, P = 0.015), but not on the Spastic Paraplegia Rating Scale, whereas stopping treatment was associated with worsening symptoms. At 2‐year follow‐up, four of five (80%) individuals chose to remain on treatment. Conclusions: HSP‐ KCNA2 is a syndrome with a recognizable variant‐specific core phenotype. Our exploratory analyses on eplerenone may serve as rationale for future investigations on targeted treatments. © 2026 International Parkinson and Movement Disorder Society.

  • Open Access

    Mitochondrial diabetes mellitus: real world insights from the GENOMIT registry–a multinational, longitudinal cohort study

    by Luisa Semmler, Boriana Büchner, Cornelia Kornblum, Marcus Deschauer, Saskia Wortmann, Chiara La Morgia, Serenella Servidei, Peter Freisinger, Alexander Mensch, Markus Schuelke, et al.

  • Open Access

    Could NQO1 genotypes impact the results of clinical trials with idebenone?

    by Valerio Carelli, Martina Romagnoli, Filippo Fortuna, Claudio Fiorini, Leonardo Caporali, Thomas Klopstock, Chiara La Morgia, Anna Maria Ghelli

    Carelli et al. argue that new insights into how NQO1 influences the response to idebenone warrant re-evaluating the results of previous clinical trials, including those in Friedreich ataxia and Duchenne muscular dystrophy, using patient stratification by NQO1 genotype.

  • Identification of Nuclear Genetic Loci Linked to Clinical Features of the m.3243A>G Mitochondrial DNA Variant

    by Róisín M. Boggan, Theodora-Dafni Michalettou, Yi Shiau Ng, Imogen G. Franklin, Lucas T. Cortés, Charlotte L. Alston, Emma L. Blakely, Boriana Büchner, Enrico Bugiardini, Kevin Colclough, et al.


  • Open Access

    A Multimodal Multiomics Machine Learning (MMM) approach for biomarker discovery and acceleration of clinical trial readiness for childhood-onset neurological disorders

    by Audrey K.S. Soo, Jenny Hällqvist, Kiran Seunarine, Robert Spaull, Ivan Doykov, Sara Guttmann, Kathleen Gorman, Apostolos Papandreou, Tian Luo, Yi Wang, et al.

    Background Childhood neurodegenerative disorders are usually rare, genetic, and life-limiting. Whilst targeted approaches present huge potential, significant hurdles include disease rarity, geographical dispersion of patients, funding, clinical trial design, and execution. Crucially, the paucity of robust biomarkers and objective measures of disease progression hampers evaluation of efficacy, drug development and regulatory approval. To address this paradigm, we developed a Multimodal Multiomics Machine Learning (MMM) framework, integrating large-scale, multi-source patient datasets to generate quantitative metrics for disease stratification and longitudinal tracking. We applied MMM to PLA2G6-associated neurodegeneration (PLAN), an ultra-rare condition currently lacking validated biomarkers, where precision gene therapy approaches are at an advanced preclinical stage. Methods A large, single time-point international natural history study (n = 310) was conducted alongside development of a disease-specific rating scale (CoPLAN-DRS), prospective longitudinal neuroimaging, and multiomic biomarker discovery. Machine learning methods were applied to the integrated dataset. Results Kaplan-Meier analyses enabled estimates for survival and time to loss of ambulation. Multiple clinical, radiological, and biofluid biomarkers were identified, clearly correlating with disease progression. The CoPLAN-DRS and brain MRI Quantitative Susceptibility Mapping showed strong positive correlation with age (rho = 0.69, 0.96 respectively). Nicastrin, a critical structural component of the gamma-secretase complex in Amyloid Precursor Protein (APP) processing, was identified as a novel biomarker. Neurofilament light levels showed strong negative correlation with disease progression (rho = -0.74). The complex multi-dimensional dataset was distilled into a simplified, clinically intuitive Digital Disease Dashboard (DDD), enabling real-time visualisation of disease severity. Conclusions Our study highlights the clinical utility of MMM in integrating multi-dimensional data from rare disease cohorts, delivering an unbiased, data-driven, optimised biomarker set. Condensing this into the DDD provides a pragmatically useful tool for clinicians, facilitating longitudinal tracking of disease. The MMM and DDD have accelerated clinical-trial readiness for PLAN, and potentially applicable to a broad range of neurogenetic disorders.


  • Open Access

    A Patient-Reported Outcome Measure of Communication Difficulties in Friedreich Ataxia: COMATAX.

    by Maresa Buchholz, Victoire Monier, Claire Ewenczyk, Anna Heinzmann, Lucie Pierron, Sabrina Sayah, Rania Hilab, Mariana Atencio, Elodie Petit, Fanny Bertrand, et al.

    Background and Objectives: Friedreich ataxia (FA) causes progressive impairment of communication due to gradual deterioration of speech, associated with impaired hearing, socio-cognitive and language skills. There is an urgent need to investigate the impact of this multiparametric alteration on patients’ lives. Therefore, the COMunication and ATAXia measure (COMATAX) was developed and validated in French and German. Methods: In the PROFA study (NCT05943002), we conducted focus groups and cognitive interviews with patients with FA, professionals and caregivers to elaborate relevant items of communication disabilities. Subsequently, the measure was validated in 93 patients with FA via a mobile health app. For validation, distribution properties, reliability (Cronbach’s alpha) and validity (correlations with VHI-30, SSQ-12, SARA total score, SARA speech item, Speech rate and GAA repeats; known-groups validity by age, sex, and self-rated health/wellbeing, disease-severity, hearing function, daily activities, and exploratory factor analysis) were calculated. An IRT analysis was performed to assess item characteristics. Results: COMATAX consists of 17 items (five response options each) and an 18th question asking about the most bothersome symptom. We observed high internal consistency for the total COMATAX scale (α = 0.897), strong correlations with VHI-30 ( r =.894), SSQ-12 ( r = −.531), moderate with SARA score ( r =.498), SARA speech item ( r =.416), Speech rate ( r =-.354), weak with GAA repeat length (r GAA1 =-0.207) and the ability to distinguish between different subgroups (disease severity, self-rated health, wellbeing, hearing function, and daily activities). Most items showed good discrimination of communication ability. Conclusion: The COMATAX is a valid and reliable patient-reported communication disability measure, useful in future therapeutic trials in FA.


  • Clinical and Genotypic Spectrum of Twinkle-Related Disorders

    by Piervito Lopriore, Zeynep Ünlütürk, Thomas Klopstock, Amel Karaa, Cecile Rouzier, Cristina Domínguez-González, Costanza Lamperti, Michelangelo Mancuso, Giulia Cecchi, Vincenzo Montano, et al.

    Twinkle, encoded by the TWNK gene, is a mitochondrial DNA helicase that unwinds the double helix of DNA during replication, playing a pivotal role in mitochondrial function. Twinkle-related disorders encompass a variety of genetic disorders characterized by mitochondrial dysfunction. Although several phenotypes have been described, the full clinical and molecular spectrum remains poorly defined. The aim of this study was to characterize the phenotypic and genotypic variability among multinational patients diagnosed with Twinkle-related disorders. A retrospective cohort study was conducted in patients with Twinkle-related disorders at several specialized centers in Italy, France, Germany, Spain, Denmark, Hungary, and the United States, establishing the Twinkle-Related Disorders International Consortium for Trial Readiness (TReDIC). Data were collected from medical records, including clinical features, age at onset, disease progression, and results from genetic testing. Phenotypic categories included infantile-onset cerebellar ataxia, parkinsonism, primary mitochondrial myopathy (PMM), multisystem involvement, asymptomatic carriers, undetermined phenotypes, and other phenotypes. All patients' diagnoses were confirmed by genetic analysis, and their genetic variants were noted. Outcomes included prevalence of phenotypes, symptom chronology, and mutational patterns. The study included a total of 189 patients (116 female), with a mean age at symptom onset of 40.3 years. At the time of analysis, 70.4% were alive. PMM was the predominant syndrome (85.2%), and most common features were progressive external ophthalmoplegia (84.7%) and skeletal myopathy (55.6%), followed by hearing loss (17.5%) and psychiatric symptoms (15.3%). Most patients (76.8%) presented with neuromuscular symptoms, with fewer showing CNS (19.6%) or multiorgan (3.6%) features at onset; by more than 8 years from onset, these proportions shifted to 54.4%, 23.3%, and 23.3%, respectively. A total of 73 TWNK variants (16 novel) were found, mostly missense, clustered in functionally critical regions. This large multinational cohort analysis advances our understanding of Twinkle-related disorders by identifying mutational hotspots with clinical relevance and illustrating the broad phenotypic spectrum and progression patterns. In the context of such rare diseases, the formation of international collaborations, such as TReDIC, can enhance our understanding and support the design of upcoming clinical trials.


  • Open Access

    The genotypic and phenotypic landscape of PDHA1 -related pyruvate dehydrogenase complex deficiency

    by Kajus Merkevicius, Dmitrii Smirnov, Lea D Schlieben, Rebecca Ganetzky, René G Feichtinger, Huafang Jiang, Fang Fang, Tomohiro Ebihara, Kei Murayama, Giulia Ferrera, et al.

    This retrospective study on X-linked PDHA1-related pyruvate dehydrogenase complex (PDHc) deficiency combined a systematic literature review with a multicentre survey exploring genotypes, phenotypes and survival. Data from 891 individuals (45% unpublished) were included. Of note, 53% of cases were females. Median age at last assessment was 6 years (range 0–80 years, n = 622). We detected 331 different (118 unpublished) PDHA1 variants, of which 75% (305/405) had occurred de novo. Variants in this study were uploaded to ClinVar (SCV006297015—SCV006297345). The 10 most frequent variants accounted for 36% of the diagnoses. Sixty-nine per cent of the variants were private; missense (50%) and frameshift (20%) variants were most common. Frameshift/nonsense (FS/N) variants in males (44/401, 11%) were confined to regions escaping nonsense-mediated decay (NMD) and were significantly less frequent than in females (151/461, 33%). Neonatal or infantile (405/529, 77%) presentations were most frequent, with pre/perinatal abnormalities reported in 47% (159/342). FS/N variants in the NMD-predicted region 3.9 [95% confidence interval (CI) 1.54–11.04] times increased the odds of fetal findings. Females presented significantly earlier [2 months, interquartile range (IQR) 7.0, n = 224] than males (8 months, IQR 16.6, n = 233), with increased risk of neonatal presentation [odds ratio (OR) 3.01 (95% CI 1.279–7.616)] when harbouring FS/N variants in the NMD-predicted region. The overall (n = 242) mean survival time was 10.9 (95% CI 9.9–11.9) years. On average, females survived 4.5 (95% CI 2.62–6.40) years longer than males despite presenting more severe phenotypes. Poor survival was associated with male sex [hazard ratio (HR) 3.3 (95% CI 1.95–5.62)], neonatal presentation [HR 5.5 (95% CI 2.17–14.09)], FS/N variants in the NMD-predicted region [HR 4.0 (95% CI 1.78, 9.16)] and splice variants [HR 2.3 (95% CI 1.15, 4.59)]. More severe clinical phenotypes were predicted by neonatal or infantile presentations and by female sex. Developmental delay (DD), intellectual disability (ID), muscle hypotonia, abnormal movements, seizures, feeding difficulties and microcephaly were the most frequent phenotypes, all occurring in more than half. Corpus callosum or basal ganglia alterations and cerebral atrophy were common. Four per cent (36/891) were reported to have mild phenotypes with no DD nor ID (25/36 males). This is the largest dataset on a nuclear-encoded defect of mitochondrial energy metabolism. The genotypic and phenotypic details further defines the disease landscape and can be used for variant interpretation. The correlations between genotypes, sex, phenotypes and survival, adds substantial improvement to counselling.


  • Open Access

    3D Quantification of Viral Transduction Efficiency in Living Human Retinal Organoids

    by Teresa S. Rogler, Katja A. Salbaum, Achim T. Brinkop, Selina M. Sonntag, Rebecca James, Elijah R. Shelton, Alina Thielen, Roland Rose, Sabrina Babutzka, Thomas Klopstock, et al.

    The development of therapeutics builds on testing their efficiency in vitro. To optimize gene therapies, for example, fluorescent reporters expressed by treated cells are typically utilized as readouts. Traditionally, their global fluorescence signal has been used as an estimate of transduction efficiency. However, analysis in individual cells within a living 3D tissue remains a challenge. Readout on a single‐cell level can be realized via fluorescence‐based flow cytometry at the cost of tissue dissociation and loss of spatial information. Complementary, spatial information is accessible via immunofluorescence of fixed samples. Both approaches impede time‐dependent studies on the delivery of the vector to the cells. Here, quantitative 3D characterization of viral transduction efficiencies in living retinal organoids is introduced. The approach combines quantification of gene delivery efficiency in space and time, leveraging human retinal organoids, engineered adeno‐associated virus (AAV) vectors, confocal live imaging, and deep learning‐based image segmentation. The integration of these tools in an organoid imaging and analysis pipeline allows quantitative testing of future treatments and other gene delivery methods. It has the potential to guide the development of therapies in biomedical applications.